Absolutely on the mark here amcfutures. You've nailed the...

Absolutely on the mark here amcfutures. You've nailed the 'Unpalatable Truth 'about PAA .
Epichem is a distraction but one thats holding the SP from further decline. Profitable ? Who knows but at least they are growing revenue. Yep large chunks of that are govt subsidies.

Like many investors I bought on prospects of their therapeutic products. Believe PAA will stand or fall on the outcomes of its phase 2 canine and human trials. Trouble is that at this stage they havent even managed to get them into a form humans can digest. Pretty hard to sell something if the patient cant take it !
Early on we had dogs chundering all over their owners lawns, next we had phase 1 human patients finding the drug 'unpalatable'(and that was years ago now). Still working on reformulating it.
In the meantime a few CRs an aborted attempt to list in USA numerous excited announcements and .......... nothing much really ! Lots of sizzle and no sausage ..yet ? SP creeps around on life support.
I continue to hold ever hopeful that this irritating little company will finally get its day in the sun. What keeps me going is that every time a subject has managed to keep the medicine down the tumour marker results have been good.